1-Methyl-2-<2-(4-dimethylamino-phenyl)-ethylen>-pyridinium | 129540-58-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Methyl-2-<2-(4-dimethylamino-phenyl)-ethylen>-pyridinium
• 英文别名: 2-(4-Dimethylaminostyryl)-1-methylpyridinium-Kation；2-(4'-Dimethylamino-styryl)-N-methyl-pyridinium；2-(4-dimethylamino-styryl)-1-methyl-pyridinium；N,N-dimethyl-4-[(Z)-2-(1-methylpyridin-1-ium-2-yl)ethenyl]aniline
• CAS: 129540-58-5；46913-87-5
• 化学式: C₁₆H₁₉N₂
• 分子量: 239.34
• InChiKey: HJWUQHBYOGZTTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  7.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  对二甲氨基苯甲醛 、 1,2-dimethyl-pyridinium 在 N-甲基哌嗪 作用下， 以 乙腈 为溶剂， 以92 %的产率得到1-Methyl-2-<2-(4-dimethylamino-phenyl)-ethylen>-pyridinium
  参考文献：
  名称：

  一种DNA嵌入型荧光淬灭化合物及其制备方法和应用

  摘要：

  本发明属于化合物技术领域，提供了一种DNA嵌入型荧光淬灭化合物及其制备方法和应用，本发明提供了一种DNA嵌入型荧光淬灭化合物，具有可见光区的吸收，具有一定的DNA序列选择性，本发明提供的DNA嵌入型荧光淬灭化合物可以进一步用于设计限制性内切酶EcoR V以及DNA酶的荧光分析体系，DNA嵌入型淬灭化合物可通过免共价标记的方式与荧光分子搭配实现相关的荧光分析，可以减少化学标记的步骤，从而提高效率、降低检测成本，在相关分析中具有较好的应用前景。

  公开号：

  CN118184643A

文献信息

• Mitochondria protecting agents for treating mitochondria associated diseases
  申请人：——

  公开号：US20020010195A1

  公开（公告）日：2002-01-24

  The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.

  本发明总体上涉及用于治疗因线粒体功能障碍导致组织退化的疾病的线粒体保护剂，以及更具体地涉及与此相关的化合物、组合物和方法。本发明的方法包括向需要它的温血动物施用药物有效量的线粒体保护剂，本发明的组合物包含与药物可接受载体或稀释剂组合的线粒体保护剂。可以通过本发明治疗的线粒体相关疾病包括（但不限于）阿尔茨海默病、糖尿病、帕金森病、神经和心肌缺血、亨廷顿病和中风。
• FLUORESCENT MOLECULAR ROTORS
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US20160195519A1

  公开（公告）日：2016-07-07

  The present invention relates to methods and compositions for detecting an interaction between a protein and a ligand, comprising: (i) binding at least one fluorescent molecular rotor to said ligand or protein; and (ii) detecting a change in fluorescence emitted by said fluorescent molecular rotor after contact of the bound fluorescent molecular rotor with the other of said ligand or protein, thereby detecting an interaction between the ligand and the protein, wherein the fluorescent molecular rotor comprises: a rotating ?-bond; an electron-donating moiety; an electron-accepting moiety; and a ?-conjugated linker.

  本发明涉及一种检测蛋白质与配体之间相互作用的方法和组合物，包括：(i)将至少一个荧光分子转子结合到所述配体或蛋白质上；和(ii)在所述结合的荧光分子转子与所述配体或蛋白质中的另一个接触后检测所述荧光分子转子发射的荧光变化，从而检测配体和蛋白质之间的相互作用，其中所述荧光分子转子包括：一个旋转的π键；一个给电子的基团；一个受电子的基团；和一个π共轭连接物。
• Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
  申请人：Terkeltaub Robert

  公开号：US20070021496A1

  公开（公告）日：2007-01-25

  The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.

  本发明涉及改进的诊断方法，用于早期检测人类发展关节炎性疾病风险，并通过比较改变的线粒体功能指标的水平，筛选用于治疗关节炎性疾病的治疗剂的检测方法。改变的线粒体功能指标包括线粒体酶和ATP合成因子等酶。其他改变的线粒体功能指标包括线粒体质量、线粒体数量、线粒体DNA含量、细胞对细胞内钙离子和凋亡原的反应，以及自由基产生。还提供了与披露的改变的线粒体功能指标相关的治疗和分层人类患者的方法。
• Compounds for altering mitochondrial function and cellular responses
  申请人：MitoKor

  公开号：US20020173543A1

  公开（公告）日：2002-11-21

  Compounds for treating diseases by altering mitochondrial function that affects cellular processes, as well as to compositions and methods related thereto. The compounds have the structure 1 wherein R 1 , R 2 , R 3 and A are as defined herein.

  通过改变影响细胞过程的线粒体功能来治疗疾病的化合物，以及与此相关的组合物和方法。这些化合物具有以下结构：其中R1、R2、R3和A的定义如下。
• Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
  申请人：——

  公开号：US20010044144A1

  公开（公告）日：2001-11-22

  Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

  本发明提供了用于制备腺嘌呤核苷酸转运蛋白（ANT）多肽和融合蛋白的组合物和方法，包括具有调节启动子的重组表达载体的制备和使用。本发明还公开了ANT配体和用于识别ANT配体、结合ANT的药剂和与ANT相互作用的药剂的组合物和方法。